Equity Overview
Price & Market Data
Price: $0.675
Daily Change: +$0.0129 / 1.91%
Range: $0.66 - $0.69
Market Cap: $34,300,596
Volume: 6,851
Performance Metrics
1 Week: -5.37%
1 Month: -22.07%
3 Months: -17.22%
6 Months: -37.80%
1 Year: -40.86%
YTD: -30.64%
Company Details
Employees: 64
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.